Chizhou Dongsheng Pharmaceutical Co., Ltd. is located in Dongzhi Economic Development Zone, Dongzhi County, Chizhou City, Anhui Province. It was established in 2006 with a registered capital of 70 million yuan and is mainly engaged in the production and sales of pharmaceutical intermediates and raw materials. Dongsheng Pharmaceutical is the first pharmaceutical raw material production enterprise in Dongzhi Economic Development Zone. It has obtained a total of 5 national brand approvals for raw materials, including fexofenadine hydrochloride, diammonium glycyrrhetinic acid, tiopronin, esomeprazole sodium, and naphazoline hydrochloride. Among them, fexofenadine hydrochloride has passed GMP certification, and multiple pharmaceutical intermediate products, such as linachlor, bosentan, vardenafil hydrochloride, and tadanafil, have been approved, We are in a leading position in both domestic and international markets. It has unique advantages in the production of high-end pharmaceutical intermediates and raw materials.

In 2022, Dongsheng Pharmaceutical introduced a large state-owned listed company, Jinling Pharmaceutical Co., Ltd., as the controlling shareholder, and Nanjing Aide Kaiteng Biopharmaceutical Co., Ltd. as the participating shareholder. Dongsheng Pharmaceutical has fully launched the overall planning and construction of new and old factory areas, as well as the comprehensive management project of safety and environmental protection facilities. In the future, Dongsheng Pharmaceutical will accelerate the high-quality development of Dongsheng Pharmaceutical through resource integration, relying on growth and strength.